Drug Profile
Research programme: peptide deformylase inhibitors - Oscient/Vernalis
Alternative Names: Metalloenzyme inhibitors - Oscient/Vernalis; Peptide deformylase inhibitors - British Biotech/GeneSoft PharmaceuticalsLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Vernalis
- Developer Oscient Pharmaceuticals; Vernalis
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 30 May 2007 Preclinical development is ongoing
- 30 Jun 2004 Compounds from this research programme are available for licensing (http://www.oscient.com)